<?xml version="1.0" encoding="UTF-8"?>
<document id="29667444">
	<sentence id="s1" text="PM were loaded with a siRNA against AKT2, an important oncogene involved in breast cancer tumorigenesis, with a special role in CSC malignancy.">
		<entity id="s1.e1" charOffset="36-40"
			type="GENE" text="AKT2" ontology_id="208"/>
		<entity id="s1.e2" charOffset="83-89"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e3" charOffset="90-95"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
	</sentence>
	<sentence id="s2" text="Efficacy of siAKT2-PM was validated in CSC isolated from two breast cancer cell lines: MCF-7 and Triple Negative MDA-MB-231 corresponding to an aggressive subtype of breast cancer.">
		<entity id="s2.e1" charOffset="14-18"
			type="GENE" text="AKT2" ontology_id="208"/>
		<entity id="s2.e2" charOffset="68-74"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
	<sentence id="s3" text="These results prompt AKT2 inhibition as a powerful therapeutic target against CSC and pave the way to the appearance of more effective nanomedicine-based gene therapies aimed to prevent CSC-related tumor recurrence">
		<entity id="s3.e1" charOffset="21-25"
			type="GENE" text="AKT2" ontology_id="208"/>
		<entity id="s3.e2" charOffset="198-203"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
</document>
